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Abstract
Key transcription factors control the gene expression program in
mature pancreatic b-cells, but their integration into regulatory
networks is little understood. Here, we show that Insm1,
Neurod1 and Foxa2 directly interact and together bind regula-
tory sequences in the genome of mature pancreatic b-cells. We
used Insm1 ablation in mature b-cells in mice and found
pronounced deficits in insulin secretion and gene expression.
Insm1-dependent genes identified previously in developing b-cells
markedly differ from the ones identified in the adult. In particu-
lar, adult mutant b-cells resemble immature b-cells of newborn
mice in gene expression and functional properties. We defined
Insm1, Neurod1 and Foxa2 binding sites associated with genes
deregulated in Insm1 mutant b-cells. Remarkably, combinatorial
binding of Insm1, Neurod1 and Foxa2 but not binding of Insm1
alone explained a significant fraction of gene expression changes.
Human genomic sequences corresponding to the murine sites
occupied by Insm1/Neurod1/Foxa2 were enriched in single nucleo-
tide polymorphisms associated with glycolytic traits. Thus, our
data explain part of the mechanisms by which b-cells maintain
maturity: Combinatorial Insm1/Neurod1/Foxa2 binding identifies
regulatory sequences that maintain the mature gene expression
program in b-cells, and disruption of this network results in
functional failure.
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Introduction
During terminal differentiation of cells, gene expression programs
are established that are then faithfully maintained throughout the
lifetime of mature cells (Holmberg & Perlmann, 2012). The ontog-
eny of pancreatic b-cells, the insulin-secreting cells of the body, has
been studied extensively, and a hierarchically controlled transcrip-
tion factor network that determines b-cell specification and differen-
tiation has been defined. Frequently, these transcription factors
provide transient regulatory input, but a subset of them remains
expressed during the lifetime of mature non-dividing b-cells
(Holmberg & Perlmann, 2012; Szabat et al, 2012). In particular,
Neurod1, Foxa1, Foxa2, Nkx6.1 and Pdx1 were first identified to
control b-cell development but are now known to also maintain
mature b-cell function (Naya et al, 1997; Ahlgren et al, 1998;
Holland et al, 2002; Gao et al, 2007, 2010; Gu et al, 2010; Szabat
et al, 2012; Taylor et al, 2013). This shows that the persistent and
mature gene expression program in b-cells is actively controlled, but
only recently the integration of these factors into regulatory
networks is beginning to receive attention (Pasquali et al, 2014).
Maturity is known to be important for b-cell function, and loss of
maturity was associated with failure of glucose-stimulated insulin
secretion in diabetes (Weir & Bonner-Weir, 2004; Ziv et al, 2013;
Wang et al, 2014). Insulin release is finely tuned and relies on mech-
anisms that allow b-cells to sense and metabolize glucose, as well as
on signaling cascades that couple metabolic signals to insulin exocy-
tosis (Lang, 1999; MacDonald et al, 2005). In addition to glucose as
primary regulator, metabolites such as free amino acids or fatty acids
also stimulate insulin secretion. Furthermore, hormones such as
glucagon-like peptide-1 (Glp1) and gastrointestinal inhibitory poly-
peptide (GIP) modulate and serve as potentiators of glucose-induced
insulin secretion (MacDonald et al, 2005; Baggio & Drucker, 2007).
Thus, in a normal physiological setting in the adult, insulin secretion
is controlled by glucose and additional signals that provide modula-
tory input. b-cells of adult and newborn mice differ in their response
to these complex cues, indicating that the ability to appropriately
1 Developmental Biology, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
2 Systems Biology of Gene Regulatory Elements, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
3 Electron Microscopy Platform, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
4 Scientific Genomics Platform, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
5 Molecular Mechanisms of Metabolic Disease, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
*Corresponding author. Tel: +49 30 9406 2403; Fax: +49 30 9406 3765; E-mail: cbirch@mdc-berlin.de
**Corresponding author. Tel: +49 30 9406 3848; Fax: +49 30 9406 3765; E-mail: jshiqi@mdc-berlin.de
‡These authors contributed equally to this work
†Present address: Department of Medical Oncology, Jiangsu Provincial Hospital of TCM, Nanjing, China
ª 2015 The Authors. Published under the terms of the CC BY NC ND 4.0 license The EMBO Journal Vol 34 | No 10 | 2015 1417
Published online: March 31, 2015 
secrete insulin is acquired during postnatal maturation. To restore
b-cells or b-cell functions in diabetic patients, in vitro protocols were
developed that allow the generation of b-cells from embryonic stem
cells by a step-wise differentiation that recapitulates development
in vivo (D’Amour et al, 2006; Nostro & Keller, 2012). Until recently,
such methods yielded immature b-cells that poorly secrete insulin in
response to glucose, but a new protocol was recently reported to
overcome this limitation (Pagliuca et al, 2014). Despite the physio-
logical importance of b-cell maturity, the maturation process
remains little understood on a molecular level.
Insm1 encodes a zinc finger factor that controls differentiation of
b-cells and other endocrine cell types in the pancreas, intestine,
pituitary and adrenal medulla (Gierl et al, 2006; Wildner et al, 2008;
Welcker et al, 2013; Osipovich et al, 2014). In endocrine cells of the
pancreas, Insm1 expression is initiated early during development in
an Ngn3-dependent manner (Gierl et al, 2006; Mellitzer et al, 2006).
Insm1 but not Ngn3 expression is maintained in mature endocrine
cells, providing an example of the distinct regulatory cascades oper-
ative in development and maturity. We show here that Insm1 binds
to chromatin in b-cells and that most Insm1 sites are co-occupied by
two key b-cell transcription factors, Neurod1 and Foxa2. Using
conditional gene ablation in mice, we show that Insm1 controls
mature b-cell function and is required for correct glucose-stimulated
insulin secretion. Mutant b-cells shift their functional properties and
gene expression program to resemble immature b-cells. Binding
sites co-occupied by Insm1/Neurod1/Foxa2 are mainly located in
intergenic and intronic sequences. Remarkably, the presence of such
combinatorial binding sites correlates very significantly with gene
expression changes in Insm1 mutant b-cells. Conversely, sites occu-
pied by Insm1 only are enriched in promoters and correlate poorly
with gene expression changes. Together, our data provide evidence
that combinatorial binding of Insm1, Neurod1 and Foxa2 identifies
cis-regulatory sequences that maintain the mature gene expression
program of b-cells.
Results
Insm1 ablation in mature b-cells abrogates glucose-stimulated
insulin secretion
In the mature murine pancreas of control mice, nuclear Insm1 protein
was detected by immunohistology in insulin+ b-cells (Fig 1A and B).
Other endocrine cell types like a-cells that express glucagon (Gcg),
d-cells that express somatostatin (Sst) and Pp-cells that express
pancreatic polypeptide (Pp) locate to the periphery of murine islets
and also express Insm1 (Fig 1C–E). In contrast to the expression
observed in developing endocrine cells, Insm1 protein levels in adult
endocrine cells appeared heterogeneous and b-cells that express high
and low Insm1 levels were observed. To assess the role of Insm1 in
mature b-cell gene regulation and function, we introduced a somatic
Insm1 mutation in mice using a ‘floxed’ allele (Insm1flox/lacZ;
Supplementary Fig S1A and Materials and Methods) and a tamoxifen-
inducible Cre driven by the insulin promoter (RIPCreER; Dor et al,
2004). To test for specificity of recombination using RIPCreER, the
mT/mG indicator line was used that expresses membrane-bound
tomato and GFP before and after Cre-dependent recombination,
respectively (Muzumdar et al, 2007). After tamoxifen treatment of
mT/mG;RIPCreER animals, the vast majority of insulin+ cells
co-expressed GFP, indicating that recombination is efficient in b-cells
(Fig 1F and G). Non-recombined tomato+ cells in islets were also
observed (Fig 1H). These co-expressed PECAM, glucagon, pancreatic
polypeptide and somatostatin (Fig 1I–L), indicating that recombina-
tion does not occur in endothelial, a-, d- and Pp-cells. We used
tamoxifen-treated mice with an Insm1flox/lacZ;RIPCreER genotype as
conditional mutants, which are subsequently called coInsm1mutants.
In coInsm1 mutants, a pronounced reduction of Insm1 protein
was observed by immunohistology in insulin+/Pdx1high b-cells
(Fig 1M–P) and by Western blot analysis of isolated islets (Fig 2A).
We next assessed plasma insulin levels in control and mutant
mice. When insulin secretion was monitored after glucose injection
in coInsm1 mutants, we observed a completely disrupted insulin
secretion; that is, insulin levels were not elevated 2, 5 or 15 min
after the injection (Fig 2B). Insulin secretion was also impaired
during a 2-h period after glucose challenge (Supplementary
Fig S1B). In fasted coInsm1 and control animals, insulin levels were
similar (Fig 2C). We also monitored insulin levels in randomly fed
animals that receive a mixture of nutrients, that is, under conditions
in which insulin secretion is regulated by complex physiological
parameters encompassing glucose, other nutrients and hormones.
This showed that insulin levels were increased in randomly fed
compared to fasted coInsm1 mice (Fig 2C). However, insulin levels
did not reach those observed in randomly fed control mice (Fig 2C).
Blood glucose levels of randomly fed coInsm1 animals were mark-
edly elevated, and coInsm1 mice showed pronounced elevation of
blood glucose in glucose tolerance tests (Fig 2D and E). Elevated
glucose levels were consistently observed in coInsm1 mice
2–11 weeks after tamoxifen treatment (Fig 2F). Similar changes in
glucose levels were observed in randomly fed and glucose chal-
lenged mice regardless whether the mutation was introduced at an
age of 1 or 2 months (compare Fig 2D and E; Supplementary Fig
S1C and D). In all experiments described above, we compared
coInsm1 mutants to control animals of two genotypes, Insm1flox/+;
RIPCreER and Insm1flox/lacZ. Since the two control groups were
indistinguishable, we combined them in subsequent experiments.
Insm1 is required for normal islet morphology and
insulin content
We next tested whether decreased insulin release was caused by
b-cell loss or reduced insulin production. Pancreatic b-cell numbers
were comparable in control and mutant mice (Fig 3A), but b-cell
mass was mildly reduced in the mutants (Fig 3B). Insulin content
and insulin-1 (Ins1) but not insulin-2 (Ins2) mRNAs were mildly
reduced in coInsm1 mutant pancreata (Fig 3C and D). Mice that lack
the insulin-1 gene remain glucose tolerant (Leroux et al, 2001), indi-
cating that the mild downregulation of insulin-1 mRNA cannot
account for the pronounced deficit in insulin secretion observed in
coInsm1 mutant mice.
Histological analyses showed that the average cell size was
reduced resulting in denser nuclear packing, but overall epithelial
cell morphology was intact as assessed by b-catenin distribution
(Fig 3E). The smaller cell size can thus account for the reduction in
the b-cell mass. TUNEL staining showed that apoptosis rates were
elevated in islets of coInsm1 mutants, but they nevertheless
remained low (< 1 apoptotic cell/section; Fig 3F). This was
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accompanied by a mild increase in proliferation (Fig 3G). We also
found that glucagon-expressing a-cells were increased in number
and dispersed throughout the islet instead of being located in the
periphery (Fig 3H). The numbers and locations of somatostatin- and
pancreatic peptide-expressing cells and expression of other
hormones were unchanged (Supplementary Fig S2). In conclusion,
ablation of Insm1 in adult b-cells resulted in perturbed islet
morphology, reduced b-cell mass due to smaller cell volume and
decreased pancreatic insulin content.
Insm1mutant b-cells assume immature functional characteristics
We next tested systematically for changes in gene expression in
coInsm1 mutant islets by microarray analysis (GSE54044), which
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Figure 1. Insm1 is expressed in adult pancreatic endocrine cells, and RIPCreER induces efficient and b-cell-specific mutation of Insm1.
A–E Analysis of Insm1 protein (red) in pancreata of adult control mice by immunohistology, using DAPI (blue) as counterstain. Insm1 is present in (A, B) b-cells that
express insulin (Ins, green), (C) a-cells that express glucagon (Gcg, green), (D) d-cells that express somatostatin (Sst, green) and (E) Pp-cells that express pancreatic
polypeptide (Pp, green). Arrowheads indicate cells co-expressing Insm1 and Gcg (C), Insm1 and Sst (D), Insm1 and Pp (E).
F–L Analysis of RIPCreER-induced recombination using mT/mG reporter mice that express membrane-bound tomato and GFP before and after Cre-mediated
recombination, respectively. The insulin+ b-cells co-express GFP and have thus undergone recombination. Cells that express tomato co-express PECAM, glucagon,
pancreatic polypeptide or somatostatin and are thus not recombined.
M, N Co-localization of Insm1 and Pdx1 in nuclei of insulin+ b-cells in control mice.
O, P Insm1 protein is lost in most b-cells of coInsm1 mice. Arrowheads indicate remaining un-recombined b-cells that continue to express Insm1; the open arrowhead
points towards an Insm1+ endocrine cell that does not co-express insulin.
Data information: Scale bars: 50 lm (A, F, H); 25 lm (E, G, L, P).
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revealed deregulated genes in mutant islets (P-value < 0.05; 1,232
genes with FC > 1.2 and < 0.8; 352 with FC > 1.4 and < 0.6). Similar
numbers of genes were up- and down-regulated. To define affected
cellular processes, we performed Gene Ontology (GO) term analysis
of differentially expressed genes. Consistent with glucose intoler-
ance, deregulated genes were associated with biological processes
critical for b-cell function, such as regulation of insulin secretion,
response to hormone and glucose stimulus, and glucose metabolism
(Fig 4A; Supplementary Table S1). Comparison with Insm1-
dependent genes identified previously in the developing pancreas
(Gierl et al, 2006) revealed little overlap (61 overlapping genes,
Pearson’s coefficient 0.21, Supplementary Table S2). Thus, Insm1
controls distinct sets of genes in developing and mature b-cells.
Insulin exocytosis from pancreatic b-cells is stimulated by
glucose metabolism by a mechanism involving ATP-sensitive K+
channels (MacDonald et al, 2005). In addition, hormones such as
glucagon-like peptide-1 (Glp1) and gastrointestinal inhibitory poly-
peptide (GIP) and metabolic fuels potentiate insulin secretion
(Baggio & Drucker, 2007). Many deregulated genes identified partici-
pate in glucose-dependent insulin secretion, such as Glut2 (Slc2a2),
Pcx, Pfkfb3, Hk1, Pdk1/4 and G6pc2 that control glucose uptake and
metabolism, a subunit of the ATP-sensitive potassium channel
(Abcc8), intracellular signaling molecules (Prckb, Ak5, Trpm5,
Cx36), glucagon-like peptide-1 receptor (Glp1r) and a negative regu-
lator of GIP receptor signaling (Rgs2) (see Supplementary Table S1
for a list of deregulated genes implicated in insulin secretion;
A B
C D
E F
Figure 2. Conditional mutation of Insm1 results in disrupted glucose-stimulated insulin secretion and glucose intolerance.
A Western blot analysis of Insm1 in isolated islets of control and coInsm1 mutant mice (pool of 200 islets from 2 to 3 mice).
B Glucose-stimulated insulin secretion in control and coInsm1 mice. The mice were injected with glucose at t = 0, and insulin secretion was monitored over time
(n = 12–14).
C Blood insulin levels in fasted and randomly fed control (green bars: Insm1flox/lacZ; blue bars: Insm1flox/+;RIPCreER) and coInsm1 mice (red bars: Insm1flox/lacZ;RIPCreER)
(n = 14–16).
D Blood glucose levels in fasted and randomly fed control and coInsm1 mice; mutations were introduced at an age of 4–5 weeks, and mice were analyzed at
8–12 weeks. Glucose levels in mutant mice were 12.3  1.3 mM (range of 4.0–24.7 mM), in contrast to 7.5  0.2 mM and 7.2  0.2 mM (range of 6.0–10.2 mM) in
control mice (n = 12–14).
E Glucose tolerance test in control and coInsm1 mice (n = 12–14).
F Blood glucose levels in randomly fed control and coInsm1 mice at various time points (0–11 weeks) after introduction of the mutations (n = 12–14).
Data information: Data are presented as means  SEM, statistical significance was assessed by ANOVA and 2-tailed unpaired Student’s t-test. *P < 0.05; **P < 0.01;
***P < 0.001.
Source data are available online for this figure.
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Babenko et al, 2006; Becker et al, 1994; Carvalho et al, 2010;
Colsoul et al, 2010; Guillam et al, 1997; Stanojevic et al, 2008;
Sugden & Holness, 2013; Tseng & Zhang, 1998; Wang et al, 2007;
Xu et al, 2008). The expression of deregulated genes implicated in
insulin secretion was confirmed by qRT–PCR (Fig 4B). Ucn3
provides a marker for b-cell maturity, and the ratio of MafB and
MafA expression is important during b-cell maturation (Artner et al,
2010; Blum et al, 2012; van der Meulen et al, 2012; Hang et al,
2014). We also observed that Ucn3,MafB andMafA were deregulated
in coInsm1 mutant islets. This provided first evidence that coInsm1
mutant islets have lost a mature gene expression program.
We therefore systematically compared genes deregulated in
coInsm1 islets to previously reported genes differentially expressed in
mature and immature (P1) murine b-cells (Blum et al, 2012;
GSE35906). This revealed a large overlap; that is, 29% of the genes
that were differentially expressed in control and coInsm1 mutant
islets were also differentially expressed in mature and immature
b-cells; a hypergeometric probability test demonstrated that this over-
lap was highly significant (P < 5.6 × 109; Fig 4C). We also compared
the differentially expressed genes of coInsm1 mutants with a diabetes
model (Kluth et al, 2014) and found a more limited overlap (115
genes deregulated in both models, P = 1). Islets of coInsm1 mutants
resemble thus more closely immature than diabetic islets. Ucn3,
Glut2 and Glp1r were among the common set of deregulated genes
in immature and coInsm1 mutant islets, and Western blotting
demonstrated reduced levels of the corresponding proteins (Fig 4D).
Ngn3 and other markers of b-cell progenitors were not induced
(Supplementary Fig S3). This indicates that coInsm1 mutant b-cells
revert to an immature but not progenitor state.
Immature b-cells, for instance those from newborn mice, are
known to respond aberrantly to glucose (Rorsman et al, 1989; Blum
et al, 2012). We therefore characterized and directly compared
glucose-induced insulin secretion from islets isolated from coInsm1
mutants and immature mice (Fig 4E and F). coInsm1 mutant but not
control islets released insulin at 3.3 mM glucose, but glucose-
stimulated insulin release was similar at 16.7 mM. In control islets,
insulin secretion was further enhanced by pyruvate, exendin-4 and
GIP in the presence of 16.7 mM glucose, but coInsm1 mutant islets
responded poorly to these secretagogues (Fig 4E). Similar changes
in insulin secretion were observed in immature islets obtained from
postnatal day 1 (P1) mice, that is, increased insulin release at low
glucose (3.3 mM) and poor response to pyruvate, exendin-4 and
GIP (Fig 4F). coInsm1 mutant islets and immature islets also
displayed a similar decrease in sensitivity to tolbutamide, a blocker
of ATP-sensitive potassium channels (Fig 4E and F). Stimulation
with KCl released similar amounts of insulin from control, coInsm1
mutant and from immature islets (Fig 4E and F). This indicated that
the overall secretory machinery remained functional in coInsm1 and
immature islets. This was also supported by electron micrograph
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Figure 3. Altered islet morphology in coInsm1 mutant mice.
A, B Comparison of b-cell number (A) and b-cell mass (B) in control and
coInsm1 mice (n = 3 mice, 6–8 slides/animal). The number given in (A)
refers to cell numbers/pancreas area.
C, D Total pancreatic level of insulin (n = 6–12) (C) and Ins1 and Ins2 mRNA
in control and coInsm1 mice (n = 5) (D).
E Epithelial morphology and quantification of the packing density of islet
cells in control and coInsm1 mice. The number given refers to cell
numbers/islet area.
F Analysis of cell death in b-cells of control and coInsm1 mice by TUNEL
staining.
G Comparison of proliferation in islets of control and coInsm1 mice using
BrdU incorporation.
H Distribution and quantification of glucagon+ cells in pancreata of control
and coInsm1 mice.
Data information: Data are presented as means  SD; statistical significance
was assessed by ANOVA and 2-tailed unpaired Student’s t-test. *P < 0.05;
**P < 0.01. (A, B, E–H) n = 3. Scale bars: 20 lm (E); 10 lm (F); 50 lm (G, H).
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Figure 4. Mutation of Insm1 disrupts mature gene expression in adult islets.
A GO term analysis of differentially expressed genes identified by microarray analysis in isolated islets from control and coInsm1 mutant mice. Shown are GO terms, the
P-value for their enrichment and the number of differentially expressed genes associated with a particular GO term.
B Verification of differential expression of genes previously implicated in the control of insulin secretion; RNA from isolated islets of control and coInsm1 mutant mice
was compared by qRT–PCR (n = 5).
C Comparison of the deregulated genes identified in coInsm1 mutant versus control islets and sorted b-cells from P1 and adult mice. 1,232 genes were differentially
expressed in coInsm1 mutant islets, and among these, 358 were previously identified as differentially expressed in immature versus mature b-cells.
D Analysis of Ucn3, Glut2 and Glp1r protein by Western blotting; a representative of three experiments is shown.
E Insulin secretion from isolated islets of control and coInsm1 mutant mice in response to glucose (3.3 and 16.7 mM), and in response to 16.7 mM glucose and
additional secretagogues, that is, 100 mM pyruvate (Pyr), 20 nM exendin-4 (Ex-4), 100 nM gastric inhibitory polypeptide (GIP), 200 lM of the ATP-sensitive K+
channel inhibitor tolbutamide (Tol) and in response to membrane depolarization (30 mM KCl) (n = 3–4).
F Insulin secretion from isolated islets of P1 and adult mice in response to glucose, secretagogues and membrane depolarization (n = 3–4).
G Secretory vesicle appearance and density in control and coInsm1 mutant b-cells (n = 3).
H Arginine-induced insulin secretion was intact in coInsm1 mutant mice (n = 6–15).
Data information: Data are presented as means  SD; statistical significance was assessed by ANOVA and 2-tailed unpaired Student’s t-test. *P < 0.05; **P < 0.01;
***P < 0.001. Scale bar: 1 lm.
Source data are available online for this figure.
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analysis of insulin-containing secretory granules in b-cells that did
not reveal changes in vesicular morphology or density in mutant
mice (Fig 4G). Furthermore, examination of arginine-induced insu-
lin secretion in vivo did not reveal significant differences between
control and coInsm1 animals (Fig 4H). Thus, mutant b-cells remain
fully capable of insulin secretion after challenge with arginine
in vivo or by global membrane depolarization by exogenous KCl
in vitro. In summary, the primary deficit in coInsm1 mutant b-cells
is restricted to glucose-induced insulin secretion and its modulation
by secretagogues, excluding a general deficit in the basic secretory
machinery. This is also supported by the fact that genes controlling
glucose sensing and metabolism, secretagogue response and intra-
cellular signaling are deregulated.
Insm1 binds to chromatin cooperatively with Neurod1 and Foxa2
To understand the molecular mechanism of Insm1 function in
b-cells, ChIP-seq experiments were performed. As a chromatin
source, we used early passages of an immortalized pancreatic b-cell
line (referred to as SJ b-cells) that we established (Radvanyi et al,
1993). Insulin secretion from SJ b-cells was stimulated eightfold to
tenfold in response to glucose, which is comparable to the response
observed in dissociated cells from adult islets, but lower than the
one in intact islets, and these cells respond to exendin-4 and GIP
(Supplementary Fig S4A; compare with Blum et al, 2012; Halban
et al, 1982). Two independent ChIP-seq experiments (GSE54046)
identified 17,453 high confidence Insm1 binding sites in chromatin
of SJ b-cells that overlapped between experiments (see Supplemen-
tary Fig S4B–D for replicate comparisons, antibody specificity and
binding site distribution). Example traces are shown in Fig 5A and
Supplementary Fig S4E (upper traces). Examination of these binding
sites by de novo motif analyses revealed an enrichment of two
sequences within 25 bp of the summits of binding sites (Fig 5Bi
and ii; E-value = 8 × 1092 and 8 × 1041 for the two motifs shown
in i and ii, respectively). The first corresponds to an E-box (present
in 22% of all Insm1 binding sites) and the second to the consensus
sequence of forkhead factors (present in 21% of all Insm1 binding
sites; Newburger & Bulyk, 2009). The previously described consen-
sus Insm1 binding sequence (Breslin et al, 2002) was not identified
by de novo motif analysis, but a related sequence (Fig 5B iii) was
observed in 19% of all Insm1 binding sites (E-value = 5.5 × 1055;
see also below).
The key b-cell transcription factors Neurod1 and Foxa2 bind
E-box and forkhead motifs, respectively. We tested whether
Neurod1 and Foxa2 co-occupy Insm1 sites in b-cell chromatin using
ChIP-seq analysis. A total of 14,607 Neurod1 and 28,379 Foxa2
binding sites were identified in the genome of SJ b-cells; 38% of the
Neurod1 and 46% of the Foxa2 sites contained the known E-box
and forkhead consensus motif, respectively, within 25 bp of the
summit of the peaks. Binding sites of Insm1 in the genome
displayed large degrees of overlap with Neurod1 and Foxa2: 73% of
all Insm1 sites were co-occupied by Neurod1 and/or Foxa2, and
38% were co-occupied by all three factors (Fig 5C). Summits of
single factor binding peaks were typically close and less than 50 bp
apart (Fig 5D). Traces for all three factors are shown for the key
b-cell transcription factor Pdx1 and the glucose transporter Glut2
(Slc2a2) (Fig 5A), as well as for Ucn3, Ins1, hexokinase1 (Hk1) and
MafA (Supplementary Fig S4E; see also Supplementary Table S3).
Many Insm1 sites not classified as Neurod1 or Foxa2 binding sites
nevertheless displayed substantial Neurod1 or Foxa2 coverage that
had not sufficed to pass the stringent cutoff (Fig 5E, Materials and
Methods). We also performed de novo motif analyses on co-occu-
pied and ‘Insm1 only’ sites. In ‘Insm1 only’ sites, two motifs were
identified, one resembling the described Insm1 consensus sequence
(Fig 5B iiii) (Breslin et al, 2002) and the second corresponding to a
new motif (Supplementary Fig S5); neither of these were identified
in sites co-occupied by all three factors.
Next, we compared the number of reads obtained in Insm1,
Neurod1 or Foxa2 ChIP-seq experiments and observed that read
numbers were highest at sites co-occupied by all three factors
(Fig 6A). Comparison of the distribution of co-occupied and ‘Insm1
only’ sites in the genome demonstrated that co-occupied sites were
depleted of promoter and enriched in intergenic and intronic
sequences (Fig 6B). The co-recruitment of Insm1, Neurod1 and Foxa2
was also experimentally tested by ChIP-PCR in both SJ b-cells and
murine islets. Indeed, all tested sites were enriched (Fig 6C and D).
Thus, Insm1, Neurod1 and Foxa2 frequently bind in close proximity
in chromatin of pancreatic b-cells, and high affinity binding sites are
enriched in sites co-occupied by all three factors.
We next tested whether Insm1 and Neurod1 and/or Foxa2 bind
simultaneously or competitively by sequential chromatin immuno-
precipitation (ChIP-reChIP) (Truax & Greer, 2012). After precipita-
tion of chromatin from SJ b-cells and murine islets by anti-Insm1
antibodies, we observed substantial re-precipitation with anti-
Neurod1 or anti-Foxa2 antibodies (Fig 7A–D). Thus, Insm1/
Neurod1 and Insm1/Foxa2 can bind simultaneously. We also tested
whether Insm1 directly interacts with Neurod1 or Foxa2 using
immunoprecipitation and Western blotting. Anti-Insm1 antibodies
co-precipitated endogenous Neurod1, and to a lesser extend Foxa2
in SJ b-cells (Fig 7E). Co-precipitation was also observed in the pres-
ence of ethidium bromide (Fig 7E), indicating that Insm1/Neurod1
and Insm1/Foxa2 interactions are independent of DNA binding (Lai
& Herr, 1992). Conversely, the endogenous Insm1 was immuno-
precipitated by anti-Neurod1 and anti-Foxa2 antibodies in the
presence and absence of ethidium bromide, but not by control or
anti-MafA antibodies (Fig 7E). Thus, Insm1 physically interacts
strongly with Neurod1, and to a lesser extent with Foxa2, indicating
that Insm1 can be recruited also indirectly to chromatin.
We chose sequences to assess them for enhancer activity in
b-cells (SJ cells), hepatocytes (HepG2 cells) and a kidney cell line
(HEK293) by luciferase assays. Sequences chosen were associated
with deregulated genes and either co-occupied by Insm1/Neurod1/
Foxa2 (indicated by 3 in Fig 7F), by other combinations of Insm1
sites (indicated by 2) or by Insm1 only (indicated by 1). The major-
ity of Insm1/Neurod1/Foxa2 co-occupied sites were more active in
b-cells than in HepG2 or HEK293 cells (Fig 7F). Thus, sites that
integrate binding of all three factors display cis-regulatory activity
and b-cell lineage selectivity. Indeed, Insm1/Neurod1/Foxa2 sites
were strongly enriched in the previously characterized putative
enhancers of b-cells (Supplementary Table S4; Tennant et al, 2013).
Six fragments that displayed lineage-specific regulatory activity
were further analyzed by luciferase assays in HepG2 cells that
express endogenous Foxa2, but not Insm1 or Neurod1. Insm1 or
Neurod1 cDNA was transfected together with luciferase constructs.
Expression of Neurod1 cDNA but not of Insm1 cDNA alone
stimulated transcriptional activity of enhancer fragments from the
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Glp1r and Pcx genes. Remarkably, Neurod1 and Insm1 co-transfection
stimulated expression synergistically (Fig 7G), which was observed
with enhancer fragments from Glp1r and Pcx genes but not other
tested fragments. We conclude from these data that Neurod1 and
Insm1 can act synergistically to increase transcriptional activity.
Combinatorial Insm1/Neurod1/Foxa2 binding sites correlate with
Insm1-dependent gene regulation
Transcription factors typically bind to many thousand sites in the
genome. It has remained a challenge to identify among these sites the
ones functionally important for regulating gene expression. We
related Insm1 binding and changes in gene expression in coInsm1
mutant islets. In comparison to all expressed genes, combinatorial
Insm1/Neurod1/Foxa2 binding sites were significantly enriched in
deregulated genes (P-value = 2.2 × 1019 and 8.0 × 1022 for
sequences 10 kb or 50 kb around the genes, respectively, for
FC > 1.2). For instance, 16% of all expressed genes and 32% of
deregulated genes (FC > 1.4) contained an Insm1/Neurod1/Foxa2
binding site within 10 kb (P-value = 4.3 × 1013). Sites occupied by
‘Insm1 only’ did not correlate with changed gene expression (Fig 8A).
Additional computational analysis of other categories of single and
combinatorial binding sites confirmed that sites co-occupied by
Insm1/Neurod1/Foxa2 correlate best with changes in Insm1-
dependent gene expression (Supplementary Table S5). Similar
numbers of genes associated with Insm1/Neurod1/Foxa2 binding sites
were up- and down-regulated (Supplementary Table S6), indicating
that these sites regulate transcription in a context-dependent manner
to activate or repress genes. Many deregulated genes associated with
combinatorial Insm1/Neurod1/Foxa2 binding sites participate in
insulin secretion, among them all deregulated genes whose expression
was verified by qPCR in Fig 3B (see Supplementary Table S3 for a list
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A Insm1, Neurod1 and Foxa2 ChIP-seq binding tracks identified in chromatin from SJ b-cells for Pdx1 and Glut2 (Slc2a2).
B De novo motif analysis of Insm1 peaks identified consensus binding sequences of basic helix-loop-helix and forkhead factors (i and ii); in addition, an Insm1 motif (iii)
identified in ‘Insm1 only’ sites that resembles the known Insm1 binding sequence is shown.
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of deregulated genes implicated in insulin secretion associated with
Insm1/Neurod1/Foxa2 sites). Finally, we defined the presence of
Insm1/Neurod1/Foxa2 binding sites in genes deregulated in both,
immature islets and coInsm1, and observed again a significant
enrichment (P-value = 1.0 × 1010 and 4.2 × 1015 for sequences
10 kb and 50 kb around deregulated genes, respectively). We conclude
that the presence of sites characterized by triple Insm1/Neurod1/
Foxa2 binding is a predictor of Insm1-dependent gene expression.
A
C
D
B
Figure 6. Sites co-occupied by Insm1, Neurod1 and Foxa2 correspond to high affinity sites and are enriched in intergenic and intronic sequences.
A Peak heights at sites occupied by individual factors, factor combinations and Insm1/Neurod1/Foxa2; median value (black line), quartiles (boxes) and errors (dashed
lines) are shown (R package). Peak heights are largest at Insm1/Neurod1/Foxa2 sites (P < 2.2 × 1016).
B Pie charts showing the distribution of Insm1 only sites (top) and Insm1/Neurod1/Foxa2 sites (bottom).
C, D ChIP-PCR analyses of Insm1, Neurod1 and Foxa2 binding in chromatin from SJ b-cells and isolated islets. Shown is the enrichment of precipitated chromatin;
representative examples of three experiments are shown.
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Figure 7. Direct interaction of Insm1, Neurod1 and Foxa2.
A reChIP-PCR analysis of selected binding sites in chromatin from SJ b-cells using antibodies against Insm1, Neurod1 and control IgG. Displayed is the percentage of
the re-precipitated chromatin divided by chromatin input.
B reChIP-PCR analysis of chromatin from isolated islets using antibodies against Insm1, Neurod1 and control IgG. Displayed is the percentage of the re-precipitated
chromatin divided by chromatin input.
C reChIP-PCR analysis of chromatin from SJ b-cell using antibodies against Insm1, Foxa2 and control IgG.
D reChIP-PCR analysis of chromatin from isolated islets using antibodies against Insm1, Foxa2 and control IgG.
E Co-immunoprecipitation of Insm1 and Neurod1, Insm1 and Foxa2 (but not Insm1 and MafA) in the presence or absence of ethidium bromide (EtBr). IP: antibody used
for immunoprecipitation. The antibody used for Western blotting is also indicated. Representative results from one of three experiments are shown
F Luciferase reporter assay for cis-regulatory activity of DNA fragments associated with deregulated genes and Insm1 binding sites; luciferase reporter assays were
performed in SJ b-cells, HepG2 and HEK293 cells. y-axis: luciferase activity relative to that of a plasmid with minimal promoter (pGL4-minP). x-axis: DNA regions co-
occupied by Insm1/Neurod1/Foxa2 (category 3), Insm1/Neurod1 or Insm1/Foxa2 sites (category 2), or ‘Insm1 only’ (category 1) (n = 4).
G Synergistic transcriptional activation of fragments from the Glp1r and Pcx genes by Neurod1 and Insm1 in HepG2 cells (n = 4); *P < 0.05.
Data information: (A–D) Representative results from experiments done in triplicate (A, C) and duplicate (B, D) are shown. Data in (F, G) are presented as means  SEM.
Source data are available online for this figure.
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Trait-associated variations in the genome (e.g., single nucleotide
polymorphisms, SNPs) are often enriched in regulatory sequences
(Hnisz et al, 2013; Pasquali et al, 2014). We defined human
sequences that correspond to the experimentally identified Insm1
binding sites in mice and correlated them with known trait-
associated variations. First, we examined SNPs obtained from the
National Human Genome Research Institute (NHGRI) GWAS cata-
logue and included 14 traits, including traits associated with b-cell
dysfunction such as diabetes, changed insulin and glucose levels.
The most pronounced enrichment was observed for sites co-occupied
by Insm1/Neurod1/Foxa2, and this was observed in SNPs associated
with ‘glucose levels’, but sites occupied by ‘Insm1 only’ were not
enriched (Fig 8B and C). Enrichment of other site categories or trait
categories did not reach this level of significance (Fig 8D; Supple-
mentary Table S7 for 98 combinations of binding site categories and
their enrichment in SNPs associated with various traits). Several
SNPs associated with type 2 diabetes were also located in Insm1/
Neurod1/Foxa2 sites, but these were not significantly enriched.
To further examine sequence variations, we also included SNPs
identified in the largest available genome-wide association analyses
for glycolytic traits (Morris et al, 2012; Scott et al, 2012) and again
observed a significant enrichment of Insm1/Neurod1/Foxa2 sites
(SNPs overlapping with Insm1/Neurod1/Foxa2 sites are listed in
Supplementary Table S8). Thus, combinatorial Insm1/Neurod1/
Foxa2 binding sites are enriched for sequences implicated in b-cell
dysfunction in humans.
Discussion
Functional immaturity was associated with failure of pancreatic
b-cells in disease (Weir & Bonner-Weir, 2004; Dor & Glaser, 2013;
Wang et al, 2014). However, mechanisms that allow the acquisition
and maintenance of the mature b-cell state are incompletely under-
stood. We show here that Insm1 is required in adult b-cells to main-
tain the mature gene expression program. Conditional Insm1 ablation
in mature b-cells leads to pronounced deficits in insulin secretion and
to glucose intolerance, and mutant islets from adult mice resemble in
these functional properties b-cells isolated from newborn animals.
We used cultured cells as a model to analyze molecular mechanisms
of Insm1 function and found that Insm1 binds to defined domains in
chromatin that are mostly co-occupied by Neurod1 and Foxa2.
Indeed, the presence of sites co-occupied by the three transcription
factors correlates significantly with gene expression changes observed
in Insm1 mutant islets. Together, our data identify Insm1 as a compo-
nent of an important transcriptional network that controls the gene
expression program of mature pancreatic b-cells.
Functional interactions between Insm1, Neurod1 and Foxa2
Our analyses show that in b-cells Insm1 is frequently bound to chro-
matin together with Neurod1 and Foxa2, two well characterized
transcription factors that control mature b-cell function (Naya et al,
1997; Lantz et al, 2004; Gao et al, 2007, 2010; Gu et al, 2010;
Mastracci et al, 2013). Cultured and primary b-cells differ in impor-
tant parameters like proliferative activity. SJ b-cells resemble but
are not identical to islets in their ability to secrete insulin in
response to glucose. Furthermore, the cultured cells also respond to
exendin-4 and GIP. Because of the ample material provided by
cultured cells, we used SJ b-cells as model for ChIP-seq experiments
and identified Insm1, Neurod1 and Foxa2 binding sites. A set of
the binding sites associated with genes known to control glucose-
dependent insulin secretion was re-tested in ChIP-PCR experiments,
and all tested sites were occupied also in isolated islets. cis-regulatory
A
B C D
Figure 8. Sites co-occupied by Insm1, Neurod1 and Foxa2 correspond to a functionally important subclass of Insm1 sites.
A Proportions of all expressed and deregulated genes containing sites bound by Insm1/Neurod1/Foxa2 within 10 kb and 50 kb of the transcription start site (left).
Proportions of all expressed and deregulated genes with sites occupied by Insm1 only 10 kb and 50 kb of the transcription start site (right). P-values for the
enrichment of genes are indicated. NS: P-value > 0.01; ***P-value ≤ 1010.
B, C SNPs with genome-wide association for 14 traits in European individuals overlapping with Insm1/Neurod1/Foxa2 and Insm1 only sites; note that SNPs associated
with fasting glucose levels are significantly enriched in Insm1/Neurod1/Foxa2 but not in sites bound by Insm1 only.
D SNPs with genome-wide association for glycolytic traits in European individuals that overlap with different combinations of Insm1, Neurod1 and Foxa2 binding
sites; P-values are displayed as log10 values. Thus, SNPs associated with Insm1/Neurod1/Foxa2 binding sites are highly enriched for glycolytic traits.
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modules that assemble many transcription factors are known to
control gene expression (Davidson, 2001; Bonn & Furlong, 2008;
Ciofani et al, 2012). Interestingly, Insm1/Neurod1/Foxa2 binding
sites identified in the Pdx1, MafA and Hadh genes were previously
shown to possess enhancer activity (Gerrish et al, 2000; Lantz et al,
2004; Raum et al, 2006). Similarly, a large proportion of the identi-
fied sequences tested experimentally displayed cis-regulatory activ-
ity and b-cell lineage selectivity.
We show here that Insm1, Neurod1 and Foxa2 do not only co-
occupy chromatin in b-cells, but Insm1 also directly interacts and
co-precipitates with Neurod1 and Foxa2 in the absence of DNA
binding. Insm1/Neurod1/Foxa2 binding sites represent high affinity
sites, as judged from the number of reads in ChIP-seq experiments.
Moreover, in cultured hepatocytes that express Foxa2 endoge-
nously, ectopic expression of Insm1 and Neurod1 can synergistically
stimulate transcriptional activity in luciferase assays when frag-
ments containing Insm1/Neurod1/Foxa2 binding sites were tested.
Remarkably, sites co-occupied by Insm1/Neurod1/Foxa2 predict a
large proportion of the Insm1-dependent gene expression in mature
b-cells, and the majority of these are located in intergenic and
intronic sequences. In contrast, sites that bind Insm1 only correlate
poorly with changed gene expression and are frequently enriched in
promoters. Our data explain part of the mechanism by which b-cells
maintain maturity and are in accordance with previous findings in
other cell and tissue types that indicate that combinatorial transcrip-
tion factor binding can be used to identify functionally important
cis-regulatory sequences (Davidson, 2001; Bonn & Furlong, 2008;
Ciofani et al, 2012).
We further show that the combinatorial binding of Insm1/
Neurod1/Foxa2 seems to some degree be conserved and function-
ally important in humans. Such sequences, when mapped to the
human genome, were enriched in human sequence variants associ-
ated with glycolytic traits. Sites co-occupied by Insm1/Neurod1/
Foxa2 represent thus a functionally important sub-class of Insm1
binding sites in the genome. However, the presence of Insm1/
Neurod1/Foxa2 sites is found in genes that are positively or nega-
tively de-regulated in coInsm1 mutant b-cells. A large fraction
(46%) but not all Insm1/Neurod1/Foxa2 sites locate to previously
mapped putative enhancer sequences of islets (Tennant et al, 2013).
Remaining sites might correspond to promoters or poised enhancers
containing bivalent histone marks that are thought to respond to
external stimuli (Creyghton et al, 2010). Together, these data indi-
cate that Insm1 acts as a transcriptional regulator and, in a context-
dependent manner, as activator or repressor, together with other
factors that modify the function of Insm1/Neurod1/Foxa2. Insm1 is
known to recruit histone-modifying factors such as Kdm1a, Hdac1/
2, Rcor1-3 and other proteins implicated in transcriptional regula-
tion (Hmg20a/b and Gse1) via its SNAG domain (Welcker et al,
2013), and our ongoing work indicates that the recruitment of such
factors explains many but not all Insm1-dependent functions in the
pancreas (Ulrich Ko¨stner and C.B., unpublished data).
Functional deficits and islet immaturity in coInsm1 mutant islets
The development and maintenance of a mature functional state of
b-cells and other cell types depends on the continuous presence of
key transcription factors that define cellular identity (Holmberg &
Perlmann, 2012). Nevertheless, distinct genes depend on Insm1
during development and in the adult, and furthermore, DNA bind-
ing by Insm1 appears to be dynamic. Thus, only a small proportion
(4.9%) of Insm1-dependent genes identified in mature b-cells were
also deregulated in developing Insm1 mutant pancreata, and among
the five known Insm1 binding sites identified previously in develop-
ing b-cells, only one located in the Insm1 promoter was also identi-
fied in this study (Gierl et al, 2006; Osipovich et al, 2014). In
addition, this analysis and previous work demonstrate that mutation
of transcription factors in mature b-cells is less disruptive than
mutation during development. For instance, among the few
commonly deregulated genes identified after Insm1 mutation in
developing and mature b-cells, we identified Insulin-1 (Ins1) that
was downregulated twofold and 13-fold after mutation of Insm1 in
adult and developing b-cells, respectively. The mature gene expres-
sion program of b-cells appears therefore to be more stable, possibly
due to epigenetic modifications or the existence of more complex
and redundant transcription factor networks.
We show here that conditional ablation of Insm1 in b-cells of
mice results in a failure to secrete insulin in response to glucose
challenge. Our data indicate that deficits in glucose uptake and
metabolism as well as changes in secretagogue response account for
this. Thus, coInsm1 mutant b-cells respond poorly to high glucose
and to modulators of glucose-dependent insulin secretion like
incretin or pyruvate. The primary deficit is restricted to glucose-
dependent insulin secretion and its modulation by secretagogues.
Mutant b-cells remain fully capable of insulin secretion after chal-
lenge with arginine or global membrane depolarization with exoge-
nous KCl in vitro, excluding a general deficit in the basic secretory
machinery. Insulin secretion from isolated islets of coInsm1 mutant
mice and immature (P1) islets under various conditions shows
remarkable physiological similarities. Furthermore, comparison of
differentially expressed genes reveals a large overlap between
coInsm1 mutant islets and immature b-cells. Thus, mutant b-cells
resembled b-cells isolated from newborn animals, but we did not
detect evidence for a return to a progenitor state marked for instance
by Ngn3 expression. We noted that Insm1/Neurod1/Foxa2 sites
with high factor occupancy cluster around genes important for b-cell
identity, for instance Pdx1 and Ins1. Further analyses will show
whether such clusters correspond to ‘super enhancers’ that were
proposed to dominate the transcriptional control of cell identity
(Hnisz et al, 2013), and to what extent such ‘super enhancers’ change
during development and maturation in temporal dynamic patterns.
Materials and Methods
Animals and genotyping analysis
The Insm1flox allele was generated using homologous recombination
in embryonic stem (ES) cells (Supplementary Fig S1A). The neomy-
cine casette used for selection in ES cells was removed by standard
techniques (Rodriguez et al, 2000). Control (Insm1flox/+;RIPCreER or
Insm1flox/lacZ) and conditional mutant (Insm1flox/lacZ;RIPCreER) mice
were generated by using RIPCreER (Dor et al, 2004) and Insm1LacZ/+
(Gierl et al, 2006) strains. Male animals at an age of 8–12 weeks
were used. Tamoxifen pellets (25 mg, 21 d release) were inserted
under the skin of 4- or 8-week-old mice (control and conditional
mutant animals). ThemT/mG reporter strain was used for verification
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of recombination (Muzumdar et al, 2007). Phenotypes were
analyzed on a mixed C57Bl/6;129Ola background and mutants
were always compared with littermates. RIPCreER was reported to
be expressed also in brain neurons, but Insm1 is solely expressed in
neuronal progenitor cells but not neurons, precluding recombina-
tion in the nervous system. Genotyping primers are listed in Supple-
mentary Table S9. All breeding, housing and experiments were
conducted in accordance with institutional German regulations.
Quantification of insulin levels, glucose levels and b-cells
Blood glucose and blood insulin measurements were performed as
described (Poy et al, 2009). Average blood glucose levels were
determined from average levels of at least six independent measure-
ments of 12–14 individual animals/genotype. For blood insulin
levels, average levels were determined from average values
obtained from at least two independent measurements of 14–16
individual animals/genotype. Sample sizes chosen were similar as
the ones previously reported to provide statistical significance
(Kulkarni et al, 2002; Kubota et al, 2004; Poy et al, 2009). For
glucose tolerance tests, glucose was injected intraperitoneally
(2 g/kg body weight), and blood glucose levels were measured
using a glucose meter (Bayer, Leverkusen, Germany). For insulin
secretion, glucose (2 g/kg body weight) or arginine (0.3 g/kg body
weight) was injected intraperitoneally, and insulin was measured
from serum using an ultra sensitive mouse insulin ELISA kit (Crystal
Chem. Inc., Downers Grove, USA). Pancreatic insulin content was
determined from pancreas tissue extracted with acid ethanol using
ELISA (Poy et al, 2009). In short, 3 pancreata/genotypes were
collected in 5 ml acidic ethanol (2% concentrated HCl in 100%
ethanol) and grinded. After centrifugation, supernatants were
collected, and insulin concentration was determined by ELISA
(Mouse High Range Insulin ELISA, Alpco, USA).
Pancreatic Ins1 and Ins2 mRNA was determined by qRT–PCR.
The b-cell mass and b-cell number/mm2 pancreas were determined
as described using 3 mice/genotype (Poy et al, 2009). In short,
every 20th sections (8 lm) of pancreata were collected, that is, 6–8
sections/pancreas encompassing the whole organ, and b-cell area
was identified by immunohistology using anti-insulin antibodies.
The entire pancreas area, insulin-positive area and pancreas weight
before sectioning were determined and used to calculate b-cell mass.
The number of b-cells/pancreas area was determined from counts
of b-cells (DAPI+ nuclei in insulin+ area) on sections of 90–120
islets/mouse.
Immunohistochemistry, immunoprecipitation and Western blot
Immunohistochemistry was performed as described by Poy et al
(2009). Fluorescence was imaged on a Zeiss LSM 700 confocal
microscope and processed using Adobe Photoshop software. Immu-
noprecipitation and Western blot were performed as described
(Welcker et al, 2013). Antibodies used are listed in Supplementary
Table S9. For co-immunoprecipitations, SJ b-cells were lysed and
centrifuged, and the supernatant was incubated with the indicated
antibodies. Antibodies were immobilized on protein A or G beads
and used to precipitate endogenous proteins. Beads were washed 3
times with PBS containing 0.02% Tween-20, and protein was eluted
using 4% SDS in 0.1 M Tris–HCl pH 7.4.
Isolation of pancreatic islets and analysis of insulin secretion
from isolated islets
Pancreatic islets were isolated as described by Poy et al (2009).
After enrichment on Histopaque (Sigma-Aldrich, Munich, Germany)
step gradients, individual islets were picked with a pipette under the
microscope.
Insulin secretion from isolated islets (n = 3–4) and SJ b-cells
(n = 3) was measured after incubation with the various secreta-
gogues (Poy et al, 2004). For this, isolated islets were cultured over-
night in RPMI medium (Gibco, Darmstadt, Germany) containing
10% fetal calf serum for recovery. Islets were prepared for analysis
by washing in secretion buffer (137 mM NaCl, 0.9 mM CaCl2,
2.7 mM KCl, 1.5 mM KH2PO4, 0.5 mM MgCl2, 8.1 mM Na2HPO4,
20 mM HEPES pH 7.4, 0.2% BSA), incubation in secretion buffer
containing 5.5 mM glucose (30 min) and again washing in secretion
buffer. The assay was then performed by incubation for 30 min in
secretion buffer containing indicated concentrations of glucose and
secretagogues. Released insulin was quantified using ELISA (Mouse
High Range Insulin ELISA, Alpco, USA).
Microarray analysis
Total RNA from isolated islets was isolated using TRIzol reagent
(Invitrogen, Carlsbad, USA). Genome-wide transcript analysis was
performed using Affymetrix GeneChip Mouse Genome 430 2.0
arrays (8 microarrays/genotype, Grossmann et al, 2009) according
to the manufacturer’s protocol. Microarray data were analyzed with
R bioconductor package (Huber & Gentleman, 2004) and processed
with affy and limma packages. To compare samples, we applied
log2 transformation and normalized with the ‘quantile’ method.
Only probes with log2 intensity > 7 were considered for further
analysis. The Benjamini–Hochberg FDR method was used to calcu-
late P-values (cutoff 0.05). The significance of overlaps in gene
expression changes in various models was compared using the
hypergeometric probability test http://www.geneprof.org/Gene-
Prof/tools/hypergeometric.jsp.
qRT–PCR analysis
For qRT–PCR analysis, cDNA from five animals/genotype was
synthetized using SuperScript III (Invitrogen) and independently
analyzed using Absolute qPCR SYBR Green mix (AbGene) on a Bio-
Rad C1000 Thermal Cycler (Sheean et al, 2014). Expression levels
were determined using the 2-DDCt method using ActB as internal
standard.
ChIP-seq and ChIP-PCR
We generated a new pancreatic b-cell line using a described protocol
(Radvanyi et al, 1993) in order to obtain cells with low passage
number and good physiological response to glucose for ChIP-seq
analysis.
Specificities of anti-Insm1 antibody were tested by immunohisto-
chemistry and Western blotting on tissue from control and Insm1
mutant mice, and of Neurod1 and Foxa2 antibodies by Western
blotting (Supplementary Fig S4C). Chromatin precipitation was done
essentially as described by Lee et al (2006). The PCR primers used
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for chromatin analysis are shown in Supplementary Table S9. ChIP-
PCR performed with anti-Insm1, anti-Neurod1 and anti-Foxa2 anti-
bodies relied on the use of protein A (Insm1, Neurod1) and protein G
(Foxa2) beads. Shown for ChIP-PCR are data from one experiment
representative of 2–3 samples (Gao et al, 2008).
Chromatin-immunoprecipitated DNA was used to prepare Illu-
mina ChIP-seq (Insm1, Neurod1, Foxa2 and IgG controls) libraries
according to the manufacturers’ protocol. In brief, starting from
10–20 ng of ChIP-DNA, the following library preparation steps
were performed for each sample (Pasquali et al, 2014): end-repair,
A-tailing, adapter ligation, gel purification and a final PCR enrich-
ment. After quality control on an Agilent Bioanalyzer and quantifi-
cation of the final library on a Qubit, we proceeded with cluster
generation and sequencing. Single-end 51-nt reads were generated,
and reads that did not pass the Illumina chastity filter were filtered
out. The number of reads obtained from the libraries used to
compare Insm1 (148 × 106, 189 × 106), Neurod1 (114 × 106) and
Foxa2 (36 × 106, 45 × 106) sites was on average 79% mappable
(see also computational analyses). The data were visualized using
the UCSC genome browser.
Computational analyses
Reads obtained by sequencing of the libraries were mapped to the
mouse (mm9) genome using Bowtie. Reads that mapped with
more than 2 mismatches or to more than one position were
discarded from further analysis. Peaks were called using Macs
software (Zhang et al, 2008) with default parameters. To visualize
peaks in UCSC genome browser, the Bowtie output was converted
to a BigWig format. We assigned a read cutoff to binding sites.
For the first Insm1 ChIP-seq experiment, a peak height of 60 was
taken as a cutoff. The cutoffs of all further experiments were
accordingly normalized to the total number of mapped reads. Two
independent ChIP-seq data sets for Insm1 and Foxa2 binding were
generated, and we considered only those sites present in both
replicates for further analysis (Supplementary Fig S4B). The two
replicates of Neurod1 were dissimilar in coverage but displayed
large overlap; for the analysis, the single data set with higher
coverage was used.
Start and end coordinates of the binding sites were defined as the
positions were the number of reads reached 50% of the peak height.
Consensus binding site coordinates were then defined as the mini-
mum start and maximum end of the peaks that were defined in the
two replicates. Binding sites were annotated as being located in
promoter, UTR, intron or exon sequences using the UCSC RefSeq
table. When a particular binding site fell into several categories, it
was scored only once, according to the following priorities:
promoter, UTR, intron and exon. Data processing and visualization
was performed with PERL and R scripts. To define the significance
in correlation between changes in gene expression and presence of
Insm1 or Insm1/Neurod1/Foxa2 binding sites, we used Fisher’s
exact test.
Motif analysis in identified binding regions was done using
MEME (Bailey et al, 2009); 500 binding sites containing the highest
peak counts were used for analysis. To define in the entire data set
numbers of sites containing a motif, we used FIMO (Grant et al,
2011) (P-value < 103). The motif search was applied to 25 nucle-
otides around the peak mode. GO term analysis was performed by
using the MGI Gene Ontology Term Finder (http://www.informatics.
jax.org/gotools/MGI_Term_Finder.html).
The correlation between deregulated genes in coInsm1 mutant
islets and various categories of binding sites was analyzed, and the
best correlation was found for Insm1/Neurod1/Foxa2 sites. This
analysis was complicated by the fact that genes often contain two
or more binding sites (e.g., Insm1/Neurod1/Foxa2 and Insm1 only
site). Therefore, equivalent analyses were performed after
excluding genes with binding sites of multiple categories. Insm1/
Neurod1/Foxa2 sites remained the most enriched category in
deregulated genes (data summarized in Supplementary Table S5).
Insm1 sites were converted to human (hg19) coordinates with
UCSC liftOver tool. SNPs with genome-wide association for 14 traits
in European individuals were retrieved from the GWAS catalog
(P-value < 5 × 108) (Hindorff et al, 2014). The list of SNPs were
pruned using PLINK tools with the following command: –indep-
pairwise 100 10 0.2 (Purcell et al, 2007), generating a list of index
SNPs. The pruning step eliminates SNPs that are in linkage disequi-
librium and results in a list of index SNPs in which each disease
associated locus is represented by a single SNP. Each index SNP
was used to identify sequence variants in high linkage disequili-
brium (r2 > 0.8), creating a final SNP list. The variants were identi-
fied in the 1,000 Genomes Project CEU (Utah residents of northern
and western European ancestry) pilot 1 data. Insm1 binding sites
(250 bp of the start and end of the binding site defined as the
positions where the number of reads reached 50% of the peak
height) that overlapped with the final SNP list were identified. To
test for enrichment, we generated a random set of sequences of iden-
tical length with the same genome annotation (such as intron, exon,
promoter, UTR) as the Insm1 binding site data set and again tested
for the presence SNPs in these sequences. The procedure was
repeated 10,000 times. The P-values were calculated as the fraction
of runs in which the number of SNPs in random sequences was as
large or larger than the number of SNPs in Insm1 binding sites.
Electron microscopy
Pancreata from mice were fixed in 4% formaldehyde in phosphate
buffer and postfixed in 2% formaldehyde and 1% glutaraldehyde
in phosphate buffer. After treatment with 1% osmium tetroxide
and dehydration, the tissue was embedded in Poly/Bed 812 (Poly-
sciences, Inc., Eppelheim, Germany). Ultrathin sections were
stained with uranyl acetate and lead citrate and examined using a
FEI Morgagni electron microscope. Digital images were taken with a
Morada CCD camera and the iTEM software (Olympus Soft Imaging
Solutions GmbH, Mu¨nster, Germany).
Luciferase assays and siRNA experiments
DNA fragments (average size 678 bp; the exact sequence coordi-
nates are given in Supplemental Table S9) were cloned upstream of
a minimal promoter driving the firefly luciferase gene (pGL4.23
[luc2/minP] vector; Promega). The selected fragments were derived
from genes whose expression was deregulated in co-Insm1 mutant
islets and had been assigned as bound by Insm1 using ChIP-seq in
SJ b-cells and ChIP-PCR of isolated islets. Using Lipofectamine 2000
(Invitrogen), SJ b-cells, HepG2 or HEK293 cells were transfected
with the firefly luciferase plasmid containing putative cis-regulatory
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sequences; as an internal control, Renilla luciferase plasmid (pRL-TK
Renilla; Promega) was co-transfected. Cell lysates were prepared
24 h after transfection, and luciferase activity was determined using
Dual-Luciferase Reporter Assay kits (Promega). For each sample
(n = 4, Ciofani et al, 2012), firefly luciferase values were normal-
ized to Renilla luciferase values. We display relative luciferase activ-
ity as a fold change compared to empty pGL4.23 vector.
siRNAs against Insm1, Neurod1 and Foxa2 mRNAs were delivered
by electroporation using Amaxa kit V and program G-16 according to
the protocol provided by the manufacturer. Mouse Insm1 and non-
targeting control siRNAs were purchased from Dharmacon (J-049233
-09/-11/-12 for Insm1 and D-001810-10 for control). Mouse Neurod1
and Foxa2 siRNAs were purchased from Ambion (s201725, s67628).
Data availability
Relevant gene expression and ChIP-seq data have been deposited
in the GEO database under the following accession numbers:
GSE54044 and GSE54046.
Supplementary information for this article is available online:
http://emboj.embopress.org
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